DECLARATION FOR NON-PROVISIONAL PATENT APPLICATION1*

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. beneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names

are listed at 201 et seq. below, of the	e subject matter which is claime	ed and for which a par	ent is sought on the i	nvendon endred			
TARGETING ENZYMES OF THE ANTI-PROLIFERATIVE MOLECT		FOR IDENTIFICAT	TION OF ANTI-FUN	IGAL AND/OR			
and for which a patent application:							
is attached hereto and includes amendment(s) filed on (if applicable)							
was filed in the United States on September 27, 2005 as Application No. 10/551,300 with amendment(s) filed on (if applicable)							
was filed as PCT international applicable)	Application No. PCT/US2004						
I hereby authorize and request my a date and application number of said	application when known.						
I hereby state that I have reviewed a amendment referred to above	and understand the contents of t	he above identified ap	pplication, including	the claims, as ame	ended by any		
I acknowledge the duty to disclose i Regulations,§1.56.	information known to me to be	material to patentabil	ity as defined in Title	e 37, Code of Fede	eral		
I hereby claim foreign priority bene certificate listed below and have als of the application on which priority	o identified below any foreign	es Code, §119(a)-(d) of application for patent	of any foreign applica or inventor's certific	ation(s) for patent ate having a filing	or inventor's g date before that		
EARLIEST FOREIGN	APPLICATION(S), IF ANY,			F THE APPLICA	ATION		
APPLICATION NUMBER	COUNTRY		DATE OF FILING (day, month, year)		PRIORITY CLAIMED		
			***	YES □	NO 🗆		
				YES 🗆	NO 🗆		
I hereby claim the benefit under Tit	le 35, United States Code, §119	9(e) of any United Sta	tes provisional applic	cation(s) listed be	low.		
PROVISIONAL APP		FILING DATE					
60/458,067	March 27,	March 27, 2003					
		į.		•			
I hereby claim the benefit under Tit matter of each of the claims of this paragraph of Title 35, United State: as defined in Title 37, Code of Fed- national or PCT international filing	application is not disclosed in t s Code §112, I acknowledge the eral Regulations, §1.56 which b	the prior United States e duty to disclose info	s application in the mormation known to mo	anner provided by e which is materia	y the first il to patentability		
NON-PROVISIONAL	FILING DATE		STATUS				
APPLICATION SERIAL NO.		PATENTED	PENDIN	IG .	ABANDONED		
PCT/US2004/009590	March 26, 2004						
i	i l		l	1			

for use only when the application is assigned to a company, partnership or other organization.

TOTAL TANK THE COMPT TIME THE CANADA AND

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	FULL NAME OF INVENTOR	LAST NAME Trotta	FIRST NAME Christopher	MIDDLE NAME R.	
2 0	RESIDENCE & CITIZENSHIP	CITY Somerset	STATE OR FOREIGN COUNTRY New Jersey	COUNTRY OF CITIZENSHIP United States	
1	POST OFFICE ADDRESS	198 Scobee Lane	CITY Somerset	STATE OR COUNTRY ZIP CODE New Jersey 08873	
		SIGNATURE OF INVENTOR 201		10/23/2006	

Attorney Docket No.: 10589-034-999

%

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No.: 3223 Application of: Christopher R. Trotta

Art Unit: To Be Assigned Serial No.: 10/551,300

Examiner: To Be Assigned Filed: September 27, 2005

TARGETING ENZYMES OF THE For:

> TRNA SPLICING PATHWAY FOR IDENTIFICATION OF ANTI-

FUNGAL AND/OR ANTI-

PROLIFERATIVE MOLECULES

POWER OF ATTORNEY BY ASSIGNEE AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71 WITH STATEMENT UNDER 37 C.F.R. 3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned assignee of the entire interest in the above-identified subject application hereby appoints Practitioners at Customer Number 20583 all of Jones Day, whose address is 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Jones Day as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all correspondence for this application to customer no. 20583.

Statement Under 37 C.F.R. 3.73(b)

PTC Therapeutics states that it is:

the assignee of the entire right, title, and interest; or 図 an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is

in the patent application/patent identified above by virtue of either:

 \boxtimes An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office on May 18, 2006 at Reel 017905, Frame 0364.

OR	A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below: From: To: The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached.				
	Additional documents in the chain of title are listed on a supplemental sheet.				
	Copies of assignments or other documents in the chain of title are attached. [Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.					
	ASSIGNEE: PTC Therapeutics				
Date: _	October 23, 2006 Signature:				
	Typed Name: Mark E. Boulding				
	Position/Title: Senior V. P. and General Counsel				